Slingshot members are tracking this event:
Intercept Announces New OCA Data in PBC and NASH to be Presented at EASL 2016
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Intercept will present eight abstracts at the Congress, including new analyses of the Phase 3 POISE trial in PBC and Phase 2 FLINT trial in NASH. Study designs for the Phase 3 REGENERATE Trial in NASH and Phase 2 CARE trial in biliary atresia will also be presented.
In addition to the clinical study presentations and posters, two of Intercept's collaborators will be giving oral presentations on the role of nuclear receptors in metabolism and cancer and the gut liver axis. Intercept will continue to explore this area with a recently announced research collaboration to evaluate the effects of OCA and other product candidates on the microbiome in a variety of non-viral liver diseases, beginning with NASH.
Slingshot Insights Explained
Apr 14, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Pbc, Nash, Phase 3 Poise Trial, Phase 2 Flint Trial, Phase 3 Regenerate Trial, Phase 2 Care Trial, Biliary Atresia